Astrazeneca (AZN) Stock
Global pharmaceutical company with strong cancer and respiratory portfolio. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in September 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca’s latest trial wins and FDA approval are keeping the growth story front and center.
- AstraZeneca’s shares are drawing support from a run of late-stage trial wins, with new data showing its COPD drug and a lung-cancer combination both delivered meaningful results that strengthen the company’s pipeline story.
- The stock also got a boost from regulatory momentum, after the FDA granted accelerated approval for Etcamah in a new breast-cancer setting, adding another near-term commercial catalyst.
- Investors are reacting to a steady flow of oncology and respiratory headlines over the past week, which suggests AstraZeneca’s growth narrative is being reinforced by both new drug approvals and encouraging trial readouts.
AstraZeneca’s latest trial wins and FDA approval are keeping the growth story front and center.
- AstraZeneca’s shares are drawing support from a run of late-stage trial wins, with new data showing its COPD drug and a lung-cancer combination both delivered meaningful results that strengthen the company’s pipeline story.
- The stock also got a boost from regulatory momentum, after the FDA granted accelerated approval for Etcamah in a new breast-cancer setting, adding another near-term commercial catalyst.
- Investors are reacting to a steady flow of oncology and respiratory headlines over the past week, which suggests AstraZeneca’s growth narrative is being reinforced by both new drug approvals and encouraging trial readouts.
About This Stock
ASTRAZENECA PLC
AZN
Current Price
$160.17
Potential 12 Month Profit
22.97%
Sector
Healthcare
Industry
Pharmaceuticals
Ticker
AZN
Market Cap
$288.18B
Potential 12 Month Profit
22.97%
Sector
Healthcare
Industry
Pharmaceuticals
Sixth Month Growth Performance
When is the next earnings date for ASTRAZENECA PLC (AZN)?
AstraZeneca’s next earnings date is expected to be October 30, 2026. It should cover the Q3 2026 / 9M 2026 results. The company’s historical reporting pattern also points to a late-October release if the date is not formally confirmed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock with a target price of $114.08, indicating strong potential growth.
Financial Health
AstraZeneca is performing well with strong revenue, profits, and cash flow generation.
Dividend
AstraZeneca's average dividend yield of 3.12% offers a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $31.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.